Analysts expect Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) to report $-0.05 EPS on November, 14.They anticipate $0.02 EPS change or 28.57 % from last quarters $-0.07 EPS. After having $-0.06 EPS previously, Lineage Cell Therapeutics, Inc.s analysts see -16.67 % EPS growth. The stock decreased 0.81% or $0.0079 during the last trading session, reaching $0.9699. About shares traded. Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) has 0.00% since October 22, 2018 and is . It has by 0.00% the S&P500.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company has market cap of $145.14 million. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It has a 4.18 P/E ratio. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries.

More notable recent Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) news were published by: Businesswire.com which released: Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation Business Wire on September 11, 2019, also Businesswire.com with their article: Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells Business Wire published on September 04, 2019, Finance.Yahoo.com published: Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019 Yahoo Finance on September 26, 2019. More interesting news about Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) were released by: Businesswire.com and their article: Lineage Cell Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019 Business Wire published on September 05, 2019 as well as Finance.Yahoo.coms news article titled: Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019 Yahoo Finance with publication date: September 23, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View original post here:
$-0.05 EPS Expected for Lineage Cell Therapeutics, Inc. (LCTX) - The Lamp News